Injectable Cannabis Formulations from GW Pharma

GW Pharmaceuticals is experimenting with an intravenous cannabinoid formulation for treating “conditions requiring the administration of a neuroprotectant or anti-convulsive medication” (US Publication 20190314296). The IV formulation contains a cannabinoid in the concentration of 0.3 mg/ml to 50 mg/ml. For comparison, their CBD extract medication Epidiolex has a concentration of 100 mg/ml, however, it is taken orally. As expected, uses for cancer treatments are also described in the patent application. GW has completed Phase I trials for the IV formulation in patients with Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) and will consult with the FDA soon to come up with safe and efficacious study designs.

Checklist, Clinic, Daily Report, Diagnosis, Doctor